Showing 771-780 of 1691 results for "".
- Is There Really a “Migraine Personality”?https://practicalneurology.com/diseases-diagnoses/headache-pain/pn0707-migraine-pdf/31148/Comorbidity Between Migraine and Psychiatric Disorders: Clinical Insights and Management StrategiesMigraine, a prevalent neurological disorder, frequently coexists with psychiatric conditions such as depression, anxiety, and personality disorders, significantly impacting patient outcomes and healthc
- News Briefshttps://practicalneurology.com/columns/practice-management/news-briefs/31273/Recent advancements and studies in neurology offer promising insights for clinical practice. A GlaxoSmithKline-sponsored trial compared the efficacy of lamotrigine versus topiramate in 192 epilepsy patients. Results demonstrated that lamotrigine outperformed topiramate on cognitive assessments such
- Dementia Insightshttps://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/PN0305Dementia-pdf/31478/Normal Pressure Hydrocephalus (NPH) has garnered renewed attention among healthcare professionals, partly driven by recent media coverage that has highlighted its potential as a reversible cause of dementia. In his article for *Practical Neurology*, Dr. David S. Geldmacher reflects on the unexpected
- Pain Managementhttps://practicalneurology.com/diseases-diagnoses/headache-pain/0105-pain-management-pdf/31506/Recent developments over the past quarter have prompted significant reconsideration of the FDA’s approach to approving and monitoring new pain medications, particularly COX-2 selective anti-inflammatory agents. The catalyst for this shift was Merck’s global withdrawal of rofecoxib (Vioxx) in Septemb
Sporadic Inclusion Body Myositis
https://practicalneurology.com/diseases-diagnoses/neuromuscular/sporadic-inclusion-body-myositis/31556/An update on pathophysiology with diagnostic and treatment implications.- Dementia Insightshttps://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/pn1007-dementia-pdf/31106/Caffeine, the most widely consumed psychoactive substance globally, continues to be a focal point in neurological research, particularly regarding its potential impact on cognitive decline and Alzheimer’s disease (AD). Recent studies presented in Practical Neurology highlight both promising and inco
- When and How to Discontinue AED Therapy in People with Epilepsyhttps://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/pn1007Epilepsy-pdf/31115/Discontinuation of Antiepileptic Drugs: Balancing Benefits and RisksAntiepileptic drugs (AEDs) have been the cornerstone of seizure disorder management for over seven decades, evolving from phenobarbital to more than two dozen agents. A critical question arises when patients achieve seizure freedom:
- Pain Managementhttps://practicalneurology.com/diseases-diagnoses/headache-pain/pn0807-pain-mngmnt-pdf/31138/In the inaugural part of a two-part series, Dr. Charles Argoff explores the intricate relationship between neuropathic pain, sleep disturbances, and psychiatric disorders such as depression and anxiety. Neuropathic pain, arising from lesions or dysfunctions within the peripheral or central nervous s
- Dementia Insightshttps://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/pn0407-dementia-pdf/31186/As spring and summer travel seasons approach, attention often focuses on fuel prices and their impact on travel patterns. Analogously, the brain operates under a supply-and-demand framework for energy, where glucose and oxygen serve as essential “fuels.” When the brain’s energy demand surpasses supp
- Therapeutics Q&Ahttps://practicalneurology.com/columns/practice-management/therapeutics-qa/31140/Impact of SSRIs on Bone Health in Elderly Patients: Clinical InsightsRecent studies have raised concerns about the use of selective serotonin reuptake inhibitors (SSRIs) and their potential negative effects on bone health in older adults. These findings pose important considerations for neurologists